(Q46791926)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18219485%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

title

Non-Hodgkin lymphoma: retrospective study on the cost-effectiveness of early treatment response assessment by FDG-PET (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18219485%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18219485%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

author name string

G Moulin-Romsee

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18219485%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

K Spaepen

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18219485%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

L Mortelmans

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18219485%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

publication date

25 January 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18219485%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

number of pages

7

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18219485%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

volume

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18219485%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18219485%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

page(s)

1074-1080

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18219485%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00259-007-0690-0

1 January 2020

exact match

0 references

cites work

Gene expression profiling of normal and malignant CD34-derived megakaryocytic cells

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00259-007-0690-0

Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

12 December 2020

PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.

1 reference

12 December 2020

Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging

1 reference

12 December 2020

Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma

1 reference

12 December 2020

Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation

1 reference

12 December 2020

18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT

1 reference

12 December 2020

Cost determinants in aggressive non-Hodgkin's lymphoma

1 reference

12 December 2020

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma

1 reference

12 December 2020

Sensitivity analysis of cost factors for various therapy options in the treatment of follicular lymphoma

1 reference

12 December 2020

Spotlight on rituximab in non-Hodgkin lymphoma and chronic lymphocytic leukemia

1 reference

12 December 2020

Cost-effectiveness of rituximab (MabThera) in diffuse large B-cell lymphoma in The Netherlands

1 reference

12 December 2020

Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose

1 reference

12 December 2020

Current treatment of follicular non-Hodgkin's lymphoma

1 reference

12 December 2020

Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma.

1 reference

12 December 2020

Evaluation of treatment response in patients with lymphoma using [18F]FDG-PET: differences between non-Hodgkin's lymphoma and Hodgkin's disease

1 reference

12 December 2020

Assessment of Lymphoma Therapy Using (18)F-FDG PET.

1 reference

12 December 2020

Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?

1 reference

12 December 2020

Early 18F-labeled fluoro-2-deoxy-D-glucose positron emission tomography scanning in the lymphomas: changing the paradigms of treatments?

1 reference

12 December 2020

10.1007/S00259-007-0690-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18219485%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference